News & Updates
Filter by Specialty:
High-dose iberdomide shows promise in phase II SLE trial
In a phase II trial evaluating three doses of the high-affinity cereblon modulator iberdomide, the 0.45-mg dose demonstrated superiority over placebo for individuals with active, moderate-to-severe systemic lupus erythematosus (SLE).
High-dose iberdomide shows promise in phase II SLE trial
07 Jun 2022
Tofacitinib on par with TNFi in rheumatoid arthritis
Tofacitinib demonstrates similar physician- and patient-reported effectiveness to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA), according to a study.
Tofacitinib on par with TNFi in rheumatoid arthritis
19 May 2022
Musculoskeletal pain common in T2D but does not influence treatment goals
Musculoskeletal pain is a common coexisting symptom in patients with type 2 diabetes (T2D), with most patients having knee or lower back pain, a study reports. However, despite the major disability burden associated with these types of pain, it does not seem to get in the way of achieving treatment targets.
Musculoskeletal pain common in T2D but does not influence treatment goals
10 May 2022
Intensive urate lowering of little benefit to patients with erosive gout
A more intensive serum urate-lowering therapy falls short of improving bone erosion scores in patients with erosive gout, in addition to being associated with a high treatment burden, as shown in a study.